ArticleMolecular neurobiology2026
Omega-3 Fatty Acid Pretreatment Modulates Mitochondrial Quality-Control and PINK1/PARKIN-Related Gene Expression in Acute LPS-Induced Neuroinflammation.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation contributes to central nervous system injury through interconnected oxidative, glial, apoptotic, and mitochondrial responses. Omega-3 (OM-3) fatty acids are neuroprotective, but their association with mitochondrial quality-control pathways during acute neuroinflammation remains incompletely defined. This study examined the preventive effects of OM-3 pretreatment in a lipopolysaccharide (LPS)-induced neuroinflammation model. Adult female Wistar albino rats (n = 8/group) were randomly assigned to Control, LPS (5 mg/kg, intraperitoneal), LPS + OM-3 (OM-3, 0.5 g/kg/day intraperitoneally for 3 days before LPS), and OM-3 groups. Six hours after LPS administration, brain and cerebellar tissues were evaluated by histopathology, immunohistochemistry (8-OHdG, Cas-3, and GFAP), qRT-PCR for apoptosis-, antioxidant-, mitochondrial biogenesis-, and mitophagy-related transcripts, and biochemical assessment of total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI). LPS increased histopathological injury and 8-OHdG, Cas-3, and GFAP immunoreactivity; increased BAX/BCL-2, PINK1, PARKIN, and SNCA transcript levels; reduced PGC-1alpha and NRF2-related antioxidant responses; decreased TAS; and increased OSI. OM-3 pretreatment attenuated many of these changes relative to LPS alone. However, several outcomes remained significantly different from Control, indicating partial rather than complete reversal. Because PINK1 and PARKIN were measured only at the mRNA level, the findings demonstrate modulation of the transcriptional response of mitophagy-related genes and do not establish functional mitophagic flux. In this 6-h acute preventive model, OM-3 pretreatment was associated with partial neuroprotection and modulation of transcriptional markers linked to antioxidant defense and mitochondrial quality Control. Protein-level and flux assays, later time points, and post-injury treatment designs are required before functional restoration of mitophagy or therapeutic efficacy can be concluded.
Indexed as
Identifiers
42879044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.